The compound, designated as DT-109, operates by suppressing harmful bacterial populations within the gastrointestinal tract, fortifying the intestinal lining, and effectively intercepting inflammatory substances before they can migrate to the…
The novel compound, designated DT-109, tackles metabolic dysfunction-associated steatohepatitis (MASH)—a progressive and potentially life-threatening condition—by subduing harmful gut bacteria, reinforcing the fragile intestinal lining, and blocking inflammatory byproducts before they…
An experimental drug developed by researchers at Michigan Medicine has successfully reversed a severe and often intractable form of fatty liver disease in animal studies. Rather than focusing solely on…